Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Eledon Pharmaceuticals, Inc. | d291766dex991.htm |
| EX-32.2 - EXHIBIT 32.2 - Eledon Pharmaceuticals, Inc. | d291766dex322.htm |
| EX-32.1 - EXHIBIT 32.1 - Eledon Pharmaceuticals, Inc. | d291766dex321.htm |
| EX-31.2 - EXHIBIT 31.2 - Eledon Pharmaceuticals, Inc. | d291766dex312.htm |
| EX-31.1 - EXHIBIT 31.1 - Eledon Pharmaceuticals, Inc. | d291766dex311.htm |
| EX-23.1 - EXHIBIT 23.1 - Eledon Pharmaceuticals, Inc. | d291766dex231.htm |
| EX-2.1 - EX-2.1 - Eledon Pharmaceuticals, Inc. | d291766dex21.htm |
| 10-K - FORM 10-K - Eledon Pharmaceuticals, Inc. | d291766d10k.htm |
Exhibit 12.1
CALCULATION OF RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS
OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS
(dollars in thousands)
| For Years Ended December 31, | ||||||||||||||||||||
| 2016 | 2015 | 2014 | 2013 | 2012 | ||||||||||||||||
| Earnings (loss): |
||||||||||||||||||||
| Net Loss |
$ | (37,959 | ) | $ | (45,087 | ) | $ | (23,296 | ) | $ | (15,819 | ) | $ | (9,683 | ) | |||||
| add: Fixed charges (see below) |
232 | 278 | 173 | 122 | 114 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| $ | (37,727 | ) | $ | (44,809 | ) | $ | (23,123 | ) | $ | (15,697 | ) | $ | (9,569 | ) | ||||||
| Fixed charges: |
||||||||||||||||||||
| Interest expense on portion of rent expense representative of interest (1) |
$ | 232 | $ | 278 | $ | 173 | $ | 122 | $ | 114 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Total fixed charges |
$ | 232 | $ | 278 | $ | 173 | $ | 122 | $ | 114 | ||||||||||
| Consolidated ratios of earnings to fixed charges (2) |
N/A | N/A | N/A | N/A | N/A | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Deficiency of earnings available to cover fixed charges |
$ | (37,959 | ) | $ | (45,087 | ) | $ | (23,296 | ) | $ | (15,819 | ) | $ | (9,683 | ) | |||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Accretion of redeemable convertible preferred stock to redemption value |
$ | — | $ | — | $ | — | $ | (94 | ) | $ | (34 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Consolidated ratios of earnings to combined fixed charges and preferred stock dividends (3) |
N/A | N/A | N/A | N/A | N/A | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Deficiency of earnings available to cover combined fixed charges and preferred stock dividends |
$ | (37,959 | ) | $ | (45,087 | ) | $ | (23,296 | ) | $ | (15,913 | ) | $ | (9,717 | ) | |||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| (1) | One third of rent expense was included in the calculation as it is a reasonable approximation of the interest factor. |
| (2) | We did not record earnings for the years ended December 31, 2016, 2015, 2014, 2013 and 2012. Accordingly, our earnings were insufficient to cover fixed charges for such periods, and we are unable to disclose a ratio of earnings to fixed charges for such periods. |
| (3) | We did not record earnings for the years ended December 31, 2016, 2015, 2014, 2013 and 2012. Accordingly, our earnings were insufficient to cover fixed charges and preferred stock dividends for such periods, and we are unable to disclose a ratio of earnings to combined fixed charges and preferred stock dividends for such periods. |